Publicaciones internacionales

2022

García-Sancho AM, Bellei M, López-Parra M, Gritti G, Cortés M, Novelli S, Panizo C, Petrucci L, Gutiérrez A, Dlouhy I, Bastos-Oreiro M, Sancho JM, Ramírez MJ, Moraleda JM, Carrillo E, Jiménez-Ubieto AI, Jarque I, Orsucci L, García-Torres E, Montalbán C, Dodero A, Arranz R, De Las Heras N, Pascual MJ, López-Jiménez J, Spina M, Re A, De Villambrosia SG, Bobillo S, Federico M, Caballero D. Autologous stem cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FILstudy. Haematologica. 2022 Mar 24. doi: 10.3324/haematol.2021.279426. Ver articulo completo: Garcia-Sancho Haematologica

Ribera JM, García O, Buendía-Ureña B, Terol MJ, Vicent A, Vall-Llovera F, Bergua J, García-Cadenas I, Esteve J, Ribera J, Acuña-Cruz E, Herrera P, Hernández-Rivas JM, Abrisqueta P, González-Campos J, Rodríguez C, Bastos-Oreiro M, Genescà E, Caminos N, Queipo de Llano MP, Cladera A, Sancho JM; Members of PETHEMA: Josep-Maria Riberaa, Olga Garcíaa, Ferran Vall-Lloverae, Juan Berguaf, Irene García-Cadenasg, Jordi Esteveh, Jordi Riberaa, Evelyn Acuña-Cruzi, Jesus-Maria Hernández-Rivas, José González-Camposm, Eulàlia Genescàa, Maria-Paz Queipo de Llanoq, Antònia Claderar Members of GELTAMO: Buenaventura Buendía-Ureñab, Maria-José Terolc, Ana Vicentd, Pilar Herreraj, Pau Abrisquetal, Carlos Rodríguezn, Mariana Bastos-Oreiroo, Nerea Caminosp, Juan-Manuel Sanchoa Groups. Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain Leuk Lymphoma. 2022 Mar 27:1-4. doi: 10.1080/10428194.2022.2053531. Online ahead of print. PMID: 35343365 Ver articulo completo: Ribera JM Leuk Lymph

Eva Gine, MD; Fatima de la Cruz, MD; Ana Jimenez Ubieto, PhD; Javier Lopez Jimenez, PhD ; Alejandro Mart?n Garc?a-Sancho, MD3,7,8; M. Jose Terol, MD ,10; Eva Gonzalez Barca, MD ´ 11; Mar?a Casanova, MD12; Adolfo de la Fuente, MD13; Ana Mar?n-Niebla, PhD14; Ana Muntañola, MD15; Tomas Jose Gonzalez-Lopez, PhD; Marta Aymerich, PhD2,3,17,18; Xavier Setoain, MD2,18,19,20; Montserrat Cortes-Romera, MD21; Amanda Rotger, MD22; Sonia Rodr?guez, MD18,23; Alejandro Medina Herrera, PhD3,7,24,25; Ramon Garc?a Sanz, PhD3,7,24,25; Ferran Nadeu, PhD2,3,17,18; Silvia Bea, PhD 2,3,17,18; El´?as Campo, PhD2,3,17,18; and Armando Lopez-Guillermo, MD 1,2,3,18 on behalf the GELTAMO Group Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015) Ver articulo completo: Clin Oncol 2022

Mercadal S, Alañá M, Barceló MI, Bruixola G, López-Pereira P, Bobillo S, Dlouhy I, Agud RC, Molina EG, Martínez P, Cacabelos P, Muntañola A, García-Catalán G, Sancho JM, Campos I, Lado T, Salar A, Caballero AC, Solé-Rodríguez M, Velasco R; Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO) and Grupo de Estudio de Neuro-Oftalmología de la Sociedad Española de Neurología (GENOSEN) group. Br J Haematol. 2022 Mar 20 Ver articulo completo: Mercadal S. Br J Haematol 2022

2021

Mariana Bastos Oreiro, Reyes Martín, Pilar Gomez, Nieves López Muñoz, Antonia Rodriguez, Marta Liébana, Belén Navarro, Blanca Sánchez-González, Pilar Marí, Jaime Pérez de Oteiza, Antonio Gutiérrez, Leyre Bento, Eva Domingo Doménech, María Jesús Vidal, Raquel Del Campo, Elena Pérez Ceballos, María Infante, Alicia Roldán, Daniel García Belmonte, Miriam Santero, Anna Sureda, Ramón García Sanz, On Behalf Of The Geltamo Group. SEGHI Study: Defining the Best Surveillance Strategy in Hodgkin Lymphoma after First-Line Treatment. Epub 2021 Mayo 17. Ver articulo completo: M Cancers 2021

Bergesio F, De Maggi A, Coronado M, Pardal E, Plaza R, Hernández AC, Sarandeses MDP, Cortes M, Setoain X, Simó M, Rotger A, Grande C, Caballero MD,Chauvie S. The F phantom clinical trials qualification for F-FDG-PET scanning adopted by GELTAMO (Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea). Rev Esp Med Nucl Imagen Mol (Engl Ed). 2021 Mayo-Jun;40(3):149-154. English, Spanish. doi: 10.1016/j.remn.2020.06.003. Epub 2021 Jan 21. PMID: 33485832. Ver articulo completo: Rev Esp Med Nucl Imagen Mol 2021

Sancho JM, Fernández-Alvarez R, Gual-Capllonch F, González-García E, Grande C, Gutiérrez N, Peñarrubia MJ, Batlle-López A, González-Barca E, Guinea JM, Gimeno E, Peñalver FJ, Fuertes M, Bastos M, Hernández-Rivas JÁ, Moraleda JM, García O, Sorigué M, Martin A. R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ?60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group. Cancer Med. 2021 Feb;10(4):1314-1326. doi: 10.1002/cam4.3730. Epub 2021 Jan 25. PMID: 33492774; PMCID: PMC7926012. Ver articulo completo: Sancho JM Cancer Med 2021

Novelli S, Bento L, Garcia I, Prieto L, López L, Gutierrez G, Hernani R, Pérez A, Esquirol A, Solano C, Bastos M, Dorado N, Rodríguez N, Rodríguez G, Piñana JL, Montoro J, Herrera P, Luna A, Parody R, Martín C, García E, López O, Heras I, Zanabili J, Moraleda JM, Yañez L, Gutierrez A, Zudaire T, Córdoba R, Varela R, Ferra C, Martínez J, Martínez C, Gonzalez-Barca E, Martino R, Caballero D; GELTAMO and GETH. Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers. Transplant Cell Ther. 2021 Jun;27(6):493.e1-493.e8. doi: 10.1016/j.jtct.2021.03.014. Epub 2021 Mar 15. PMID: 33857447. Ver articulo completo: Novelli S Transplant Cell Ther

Bento L, Gutiérrez A, Novelli S, Montoro J, Piñana JL, López-Corral L, Cabrero M, Martín-Sancho A, Gutiérrez-García G, Ortiz-Moscovich M, Bastos-Oreiro M, Dorado N, Pérez A, Hernani R, Ferrà C, Parody R, García-Cadenas I, Herrera P, Rodríguez G, Rodríguez N, Martín C, Yáñez L, Zanabili J, Varela MR, López-Godino O, Heras I, Español I, Martínez C, Pérez-Simón JA, Solano C, Sureda A, Sierra J, Sampol A, Caballero D; Grupo Español de Trasplante Hematopoyético (GETH) and Grupo Español de Linfoma y Trasplante Autólogo (GELTAMO). Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study. Bone Marrow Transplant. 2021 Aug;56(8):1919-1928. doi: 10.1038/s41409-021-01264-3. Epub 2021 Mar 25. PMID: 33767400. Ver articulo completo: Bone Marrow Transplant 2021

Iacoboni G, Villacampa G, Martinez-Cibrian N, Bailén R, Lopez Corral L, Sanchez JM, Guerreiro M, Caballero AC, Mussetti A, Sancho JM, Hernani R, Abrisqueta P, Solano C, Sureda A, Briones J, Martin Garcia-Sancho A, Kwon M, Reguera-Ortega JL, Barba P; GETH, GELTAMO Spanish Groups. Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. Cancer Med. 2021 Mayo;10(10):3214-3223. doi: 10.1002/cam4.3881. Epub 2021 Mayo 1. PMID: 33932100; PMCID: PMC8124109. Ver articulo completo: Cancer Med 2021

López-Guillermo A, Canales MÁ, Dlouhy I, Mercadal S, Briones J, Martín García-Sancho A, Sancho JM, Moraleda JM, Terol MJ, Salar A, Palomera L, Gardella S, Jarque I, Ferrer S, Bargay J, López A, Panizo C, Muntañola A, Montalbán C, Conde E, Hernández MT, Soler A, García Marco JA, Deben G, Marín J, Tomás JF; PETHEMA/GELTAMO/GELCAB Spanish Intergroup. A randomized phase II study comparing consolidation with a single dose of Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results.Leuk Lymphoma. 2021 Aug 30:1-8. doi: 10.1080/10428194.2021.1971216. Epub ahead of print. PMID: 34459702. Ver articulo completo: A Leuk Lymph 2021

Stefania Infante M, Fernández-Cruz A, Núñez L, Carpio C, Jiménez-Ubieto A, López-Jiménez J, Vásquez L, Del Campo R, Romero S, Alonso C, Morillo D, Prat M, Luis Plana J, Villafuerte P, Bastidas G, Bocanegra A, Serna Á, De Nicolás R, Marquet J, Mas-Ochoa C, Cordoba R, García-Suárez J, Comai A, Martín X, Bastos- Oreiro M, Seri C, Navarro-Matilla B, López-Guillermo A, Martínez-López J, Ángel Hernández-Rivas J, Ruiz-Camps I, Grande C; Grupo Español de Linfomas y Trasplante Autólogo de Medula Ósea (GELTAMO). Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study. Cancer Med. 2021 Nov;10(21):7629-7640. doi: 10.1002/cam4.4293. Epub 2021 Sep 23. PMID: 34558211. Ver articulo completo: Infante Cancer Med 2021

Gonzalez de Villambrosia S, Bastos M, Palanca JM, Cruz JG, Navarro JT, Tapia G, Alonso SA, Martin A, Blanco O, Abrisqueta P, Castellvi J, García-Noblejas A, Arranz R, Adrados M, López A, Montes-Moreno S; Grupo Español de linfomas y trasplante (GELTAMO). BCL2 translocation in high grade B cell lymphoma (NOS, DH/TH) is associated with reduced progression free survival. Leuk Lymphoma. 2021 Sep 11:1-8. doi: 10.1080/10428194.2021.1975189. Epub ahead of print. PMID: 34510996. Ver articulo completo: S Leuk Lymph 2021

González-Barca E, Capote FJ, Gómez-Codina J, Panizo C, Salar A, Sancho JM, López A, Briones J, Muñoz A, Encuentra M, Mercadal S, Domingo-Domenech E, de Sevilla AF; GELTAMO (Spanish Lymphoma Group) and GOTEL (Group of Oncology for Therapy and Study of Lymphomas). Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients. Ann Hematol. 2021 Apr;100(4):1023-1029. doi: 10.1007/s00277-020-04056-9. Epub 2020 Mayo 4. PMID: 32367180. Ver articulo completo: Ann Hematol 2021

Montoro J, Chorão P, Bento L, Cabrero M, Martín C, Novelli S, Cadenas IG, Gutiérrez G, López-Godino O, Ferrá C, Bastos-Oreiro M, Pérez A, Parody R, Pérez Simón JA, Yañez L, Sánchez A, Zanabili J, Varela MR, Córdoba R, Zudaire T, Jiménez-Ubieto A, Sanz J, Sureda A, Caballero D, Piñana JL; GETH and GELTAMO Group. Risk factors and outcomes of follicular lymphoma after allogeneic hematopoietic stem cell transplantation using HLA-matched sibling, unrelated, and haploidentical-related donors. Bone Marrow Transplant. 2021 Apr;56(4):992-996. doi: 10.1038/s41409-020-01161-1. Epub 2020 Dec 12. PMID: 33311593. Ver articulo completo: Montoro J Bone Marrow Transplant 2021

Sara Alonso-Álvarez Martina Manni, Silvia Montoto, Clémentine Sarkozy, Franck Morschhauser, Marielle J Wondergem, Attilio Guarini, Laura Magnano, Miguel Alcoceba, Martine Chamuleau, Sara Galimberti, Maria Gomes da Silva, Harald Holte, Emanuele Zucca, Sandra Lockmer, Igor Aurer, Luigi Marzoeselli, Yana Stepanishyna, María Dolores Caballero Barrigón, Gilles Salles, Massimo Federico ; Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma 2021 Nov;157:132-139. doi: 10.1016/j.ejca.2021.08.005.Epub 2021 Sep 8. Ver articulo completo: S. Alonso-Alvarez refractory follicular lymphoma

2020

Salas MQ, Mercadal S, Domingo Domenech E, Oliveira AC, Encuentra M, Climent F, Andrade Campos M, Aguilera C, Fernández de Sevilla A, Sureda A, González- Barca E. Validation of the NCCN-IPI and the GELTAMO-IPI for diffuse large B-Cell lymphoma treated with R-CHOP in a large cohort of patients from a single institution. Leuk Lymphoma. 2020 Mar;61(3):575-581. doi: 10.1080/10428194.2019.1683733. Epub 2019 Nov 5. PMID: 31684781.

Bastos-Oreiro M, Muntañola A, Panizo C, Gonzalez-Barca E, de Villambrosia SG, Córdoba R, López JLB, González-Sierra P, Terol MJ, Gutierrez A, Grande C, Ramirez MJ, Iserte L, Perez E, Navarro B, Gomez P, Salar A, Luzardo H, López A, Del Campo R, García-Belmonte D, Vida MJ, Infante M, Queizan-Hernandez JA, Novelli S, Moreno M, Penarrubia M, Gómez J, Domingo A, Donato E, Viguria MC, López F, Rodriguez MJ, Pardal E, Noriega V, Andreu R, Peñalver J, Martín A, Caballero D, López-Guillermo A. RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group. Ann Hematol. 2020 Apr;99(4):799-808. doi: 10.1007/s00277-020-03918-6. Epub 2020 Feb 20. PMID: 32076827. Ver articulo completo

Gutierrez A, Bento L, Diaz-Lopez A, Barranco G, Garcia-Recio M, Lopez- Guillermo A, Dlouhy I, Rovira J, Rodriguez M, Sanchez Pina JM, Baile M, Martín A, Novelli S, Sancho JM, García O, Salar A, Bastos-Oreiro M, Rodriguez-Salazar MJ, Fernandez R, de la Cruz F, Queizan JA, González de Villambrosia S, Cordoba R, López A, Luzardo H, García D, Sastre-Serra J, Garcia JF, Montalban C, Cabanillas F, Rodríguez J. Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era. Eur J Haematol. 2020 Mayo;104(5):400-408. doi: 10.1111/ejh.13364. Epub 2020 Feb 18. PMID: 31804029; PMCID: PMC7217048. Ver articulo completo: Eur J Haematol

Novelli S, Martín A, Sánchez JJ, Espeso M, Mozos A, Briones J. Management experience of advanced-stage mycosis fungoides/Sézary syndrome: a retrospective study from Spanish haematology referral units. Eur J Dermatol. 2020 Aug 1;30(4):397-403. doi: 10.1684/ejd.2020.3840. PMID: 32815814.

Gleeson M, Counsell N, Cunningham D, Lawrie A, Clifton-Hadley L, Hawkes E, McMillan A, Ardeshna KM, Burton C, Chadwick N, Gambell J, Smith P, Mouncey P, Pocock C, Radford J, Davies J, Turner D, Kruger A, Johnson P, Linch D. Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial. Br J Haematol. 2021 Mar;192(6):1015-1019. doi: 10.1111/bjh.16691. Epub 2020 Mayo 20. PMID: 32436212.

Martínez C, Carpio C, Heras I, Ríos-Herranz E, Buch J, Gutierrez A, Romero S, Zeberio I, García-García I, Rodriguez-Izquierdo A, Alonso R, Bargay J, Barrenetxea C, Domingo-Doménech E, de Haro ME, Palomera L, García-Sanz R; Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO). Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain. Biol Blood Marrow Transplant. 2020 Aug;26(8):1534-1542. doi: 10.1016/j.bbmt.2020.02.003. Epub 2020 Feb 14. PMID: 32068094. Ver articulo completo: Biol Blood Marrow Transplant

Velasco R, Mercadal S, Vidal N, Alañá M, Barceló MI, Ibáñez-Juliá MJ, Bobillo S, Caldú Agud R, García Molina E, Martínez P, Cacabelos P, Muntañola A, García-Catalán G, Sancho JM, Camro I, Lado T, Erro ME, Gómez-Vicente L, Salar A, Caballero AC, Solé-Rodríguez M, Gállego Pérez-Larraya J, Huertas N, Estela J, Barón M, Barbero-Bordallo N, Encuentra M, Dlouhy I, Bruna J, Graus F; GELTAMO and GENOSEN group. Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study. J Neurooncol. 2020 Jul;148(3):545-554. doi: 10.1007/s11060-020-03547-z. Epub 2020 Jun 10. PMID: 32524392. Ver articulo completo: Velasco R J Neuroncol 2020

Bento L, Díaz-López A, Barranco G, Martín-Moreno AM, Baile M, Martín A, Sancho JM, García O, Rodríguez M, Sánchez-Pina JM, Novelli S, Salar A, Bastos M, Rodríguez-Salazar MJ, González de Villambrosia S, Córdoba R, García-Recio M, Martínez-Serra J, Del Campo R, Luzardo H, García D, Hong A, Abrisqueta P, Sastre-Serra J, Roca P, Rodríguez J, Gutiérrez A; Grupo Español de Linfomas y Trasplante Autólogo (GELTAMO). New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO). Br J Haematol. 2020 Mar;188(6):888-897. doi: 10.1111/bjh.16263. Epub 2019 Nov 28. PMID: 31782146. Ver articulo completo: Br J Haematol 2020

2019

Garcia-Sanz R, Sureda A, de la Cruz F, Canales M, Gonzalez AP, Pinana JL, Rodriguez A, Gutierrez A, Domingo-Domenech E, Sanchez-Gonzalez B, Rodriguez G, Lopez J, Moreno M, Rodriguez-Salazar MJ, Jimenez-Cabrera S, Caballero MD, Martinez C. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). Ann Oncol. 2019 Apr 1;30(4):612-620. doi: 10.1093/annonc/mdz009. PMID: 30657848. Ver articulo completo: Ann Oncol 2019

Redondo AM, Valcárcel D, González-Rodríguez AP, Suárez-Lledó M, Bello JL, Canales M, Gayoso J, Colorado M, Jarque I, Del Campo R, Arranz R, Terol MJ, Rifón JJ, Rodríguez MJ, Ramírez MJ, Castro N, Sánchez A, López-Jiménez J, Montes-Moreno S, Briones J, López A, Palomera L, López-Guillermo A, Caballero D, Martín A; Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO). Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group. Br J Haematol. 2019 Mar;184(5):797-807. doi: 10.1111/bjh.15713. Epub 2018 Dec 12. PMID: 30548583. Ver articulo completo: AM Redondo Bendamustine

Magnano L, Alonso-Alvarez S, Alcoceba M, Rivas-Delgado A, Muntañola A, Nadeu F, Setoain X, Rodríguez S, Andrade-Campos M, Espinosa-Lara N, Rodríguez G, Sancho JM, Moreno M, Mercadal S, Carro I, Salar A, Garcia-Pallarols F, Arranz R, Cannata J, Terol MJ, Teruel AI, Jiménez-Ubieto A, Rodriguez A, González de Villambrosía S, Bello JL, López L, Novelli S, de Cabo E, Infante ME, Pardal E, Monsalvo S, González M, Martín A, Caballero MD, López-Guillermo A; Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO). Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population. Br J Haematol. 2019 Mayo;185(3):480-491. doi: 10.1111/bjh.15805. Epub 2019 Feb 22. PMID: 30793290. Ver articulo completo: Br J Hematol 2019

Jiménez-Ubieto A, Grande C, Caballero D, Yáñez L, Novelli S, Hernández- Garcia MT, Manzanares M, Arranz R, Ferreiro JJ, Bobillo S, Mercadal S, Galeo A, Jiménez JL, Moraleda JM, Vallejo C, Albo C, Pérez E, Marrero C, Magnano L, Palomera L, Jarque I, Rodriguez A, Lorza L, Martín A, Coria E, López-Guillermo A, Salar A, José Lahuerta J; GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) Cooperative Study Group. Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy. Hematol Oncol Stem Cell Ther. 2019 Dec;12(4):194-203. doi: 10.1016/j.hemonc.2019.06.001. Epub 2019 Jul 9. PMID: 31319058. Ver articulo completo: Ubieto A Hematol Oncol Stem Cell

Coutinho R, Lobato J, Esteves S, Cabeçadas J, Gomes da Silva M. Clinical risk scores do not accurately identify a very high risk population with diffuse large B cell lymphoma-an analysis of 386 Portuguese patients. Ann Hematol. 2019 Aug;98(8):1937-1946. doi: 10.1007/s00277-019-03676-0. Epub 2019 Apr 4. PMID: 30949752.

Peñalver FJ, Márquez JA, Durán S, Giraldo P, Martín A, Montalbán C, Sancho JM, Ramírez MJ, Terol MJ, Capote FJ, Gutiérrez A, Sánchez B, López A, Salar A, Rodríguez-Caravaca G, Canales M, Caballero MD; GELTAMO (The Spanish Lymphoma Cooperative Group). Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial. Cancer Med. 2019 Nov;8(16):6955-6966. doi: 10.1002/cam4.2555. Epub 2019 Oct 1. PMID: 31573746; PMCID: PMC6853826. Ver articulo completo: Peñalver FJ Cancer Med 2019

2018

González-Barca E, Coronado M, Martín A, Montalbán C, Montes-Moreno S, Panizo C, Rodríguez G, Sancho JM, López-Hernández A; Spanish Lymphoma Group (GELTAMO). Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma. Oncotarget. 2018 Aug 17;9(64):32383-32399. doi: 10.18632/oncotarget.25892. PMID: 30190794; PMCID: PMC6122355.

Montalbán C, Díaz-López A, Martín A, Baile M, Sanchez JM, Sancho JM, García O, Novelli S, Monter-Rovira A, Salar A, Bastos M, Gutiérrez A, Bento L, Córdoba R, Arquero T, González de Villambrosia S, Barranco G, De Oña R, López Guillermo A, Rodriguez Salazar MJ, Domínguez JF, Fernández R, Queizan JA, Rodríguez J, Abraira V, García JF; GELTAMO-IPI Project Investigators. Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm. Br J Haematol. 2018 Aug;182(4):534-541. doi: 10.1111/bjh.15446. Epub 2018 Jul 5. PMID: 29978453.

Jiménez-Ubieto A, Grande C, Caballero D, Yáñez L, Hernández-Garcia MT, Novelli S, Arranz R, Ferreiro JJ, Bobillo S, Mercadal S, Galeo A, Jiménez JL, Moraleda JM, Vallejo C, Albo C, Pérez E, Marrero C, Magnano L, Palomera L, Jarque I, Martínez-Sánchez P, Martín A, Coria E, López-Guillermo A, Salar A, Lahuerta JJ; GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) Cooperative Study Group.. Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre- rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry. Bone Marrow Transplant. 2018 Jun;53(6):780-783. doi: 10.1038/s41409-018-0096-6. Epub 2018 Jan 23. PMID: 29362504.

Pardal E, Díez Baeza E, Salas Q, García T, Sancho JM, Monzón E, Moraleda JM, Córdoba R, de la Cruz F, Queizán JA, Rodríguez MJ, Navarro B, Hernández JA, Díez R, Vahi M, Viguria MC, Canales M, Peñarrubia MJ, González-López TJ, Montes- Moreno S, González-Barca E, Caballero D, Martín A; GELTAMO Spanish Collaborative Group. A new prognostic model identifies patients aged 80 years and older with diffuse large B-cell lymphoma who may benefit from curative treatment: A multicenter, retrospective analysis by the Spanish GELTAMO group. Am J Hematol. 2018 Jul;93(7):867-873. doi: 10.1002/ajh.25107. Epub 2018 Mayo 6. PMID: 29658143.

Bobillo S, Abrisqueta P, Sánchez-González B, Giné E, Romero S, Alcoceba M, González-Barca E, González de Villambrosía S, Sancho JM, Gómez P, Bento L, Montoro J, Montes S, López A, Bosch F; Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea (GEL/TAMO cooperative group). Posttransplant monomorphic Burkitt's lymphoma: clinical characteristics and outcome of a multicenter series. Ann Hematol. 2018 Dec;97(12):2417-2424. doi: 10.1007/s00277-018-3473-8. Epub 2018 Aug 16. PMID: 30116871.

Jiménez-Ubieto A, Grande C, Caballero D, Yáñez L, Novelli S, Hernández- Garcia MT, Manzanares M, Arranz R, Ferreiro JJ, Bobillo S, Mercadal S, Galeo A, Jiménez JL, Moraleda JM, Vallejo C, Albo C, Pérez E, Marrero C, Magnano L, Palomera L, Jarque I, Martínez-Sánchez P, Martín A, Coria E, López-Guillermo A, Salar A, Lahuerta JJ; GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) Cooperative Study Group. Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment. Hematol Oncol. 2018 Dec;36(5):765-772. doi: 10.1002/hon.2553. Epub 2018 Sep 12. PMID: 30129233.

Massimo Federico, María Dolores Caballero Barrigón2, Luigi Marzoeselli3, Vittoria Tarantino4, Martina Manni4, Clementine Sarkozy5, Sara Alonso-Álvarez6, Marielle Wondergem7, Guillaume Cartron8, Armando Lopez-Guillermo9, Djamila Issa10, Franck Morschhauser11, Miguel Alcoceba2, Eva Kimby12, Chiara Rusconi13, Martine Chamuleau7, Harald Holte14, Sandra Lockmer12, Silvia Montoto15, Maria Gomes da Silva16, Igor Aurer17, Emanuele Zucca18, Ewa Paszkiewicz-Kozik19, Carla Minoia20, Tetiana Skrypets4, Yngvild Nuvin Blaker14, Gilles Salles5, Bertrand Coiffier5, Aristotle Consortium Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. PMID: 30078408 Ver articulo completo: Federico 2018

2017

Hong J, Kim SJ, Chang MH, Kim JA, Kwak JY, Kim JS, Yoon DH, Lee WS, Do YR, Kang HJ, Eom HS, Park Y, Won JH, Mun YC, Kim HJ, Kwon JH, Kong JH, Oh SY, Lee S, Bae SH, Yang DH, Jun HJ, Lee HS, Yun HJ, Lee SI, Kim MK, Yi JH, Lee JH, Kim WS, Suh C. Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma. Oncotarget. 2017 Sep 18;8(54):92171-92182. doi: 10.18632/oncotarget.20988. PMID: 29190906; PMCID: PMC5696172.

Montalbán C, Díaz-López A, Dlouhy I, Rovira J, Lopez-Guillermo A, Alonso S, Martín A, Sancho JM, García O, Sánchez JM, Rodríguez M, Novelli S, Salar A, Gutiérrez A, Rodríguez-Salazar MJ, Bastos M, Domínguez JF, Fernández R, Gonzalez de Villambrosia S, Queizan JA, Córdoba R, de Oña R, López-Hernandez A, Freue JM, Garrote H, López L, Martin-Moreno AM, Rodriguez J, Abraira V, García JF; GELTAMO-IPI Project Investigators. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of ?₂ -microglobulin yields a more accurate GELTAMO-IPI. Br J Haematol. 2017 Mar;176(6):918-928. doi: 10.1111/bjh.14489. Epub 2017 Jan 20. PMID: 28106247.

Peñalver FJ, Sancho JM, de la Fuente A, Olave MT, Martín A, Panizo C, Pérez E, Salar A, Orfao A; Spanish Lymphoma Group (GELTAMO). Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO). Haematologica. 2017 Feb;102(2):235-245. doi: 10.3324/haematol.2016.149120. Epub 2016 Oct 20. PMID: 27846613; PMCID: PMC5286932.

Alonso-Álvarez S, Magnano L, Alcoceba M, Andrade-Campos M, Espinosa-Lara N, Rodríguez G, Mercadal S, Carro I, Sancho JM, Moreno M, Salar A, García-Pallarols F, Arranz R, Cannata J, Terol MJ, Teruel AI, Rodríguez A, Jiménez-Ubieto A, González de Villambrosia S, Bello JL, López L, Monsalvo S, Novelli S, de Cabo E, Infante MS, Pardal E, García-Álvarez M, Delgado J, González M, Martín A, López- Guillermo A, Caballero MD. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group. Br J Haematol. 2017 Sep;178(5):699-708. doi: 10.1111/bjh.14831. Epub 2017 Aug 7. PMID: 28782811.

García-Noblejas A, Cannata-Ortiz J, Conde E, González Barca E, Gutiérrez N, Rojas R, Vidal MJ, Ramírez MJ, Jiménez-Ubieto A, García-Ruiz JC, Sancho JM, López A, Ríos Rull P, Novelli S, Albo C, Debén G, López-Guillermo A, Nicolás C, González de Villambrosia S, Mercadal S, Martín García-Sancho A, Arranz R. Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO). Ann Hematol. 2017 Aug;96(8):1323-1330. doi: 10.1007/s00277-017-2998-6. Epub 2017 Mayo 24. PMID: 28536895.

Jiménez-Ubieto A, Grande C, Caballero D, Yáñez L, Novelli S, Hernández- Garcia MT, Manzanares M, Arranz R, Ferreiro JJ, Bobillo S, Mercadal S, Galeo A, López Jiménez J, Moraleda JM, Vallejo C, Albo C, Pérez E, Marrero C, Magnano L, Palomera L, Jarque I, Martínez-Sánchez P, Martín A, Coria E, López-Guillermo A, Salar A, Lahuerta JJ. Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure. Biol Blood Marrow Transplant. 2017 Oct;23(10):1631-1640. doi: 10.1016/j.bbmt.2017.05.021. Epub 2017 Mayo 19. PMID: 28533060.

Jiménez-Ubieto A, Grande C, Caballero D, Yáñez L, Novelli S, Hernández MT, Manzanares M, Arranz R, Ferreiro JJ, Bobillo S, Mercadal S, Galego A, Jiménez JL, Moraleda JM, Vallejo C, Albo C, Pérez E, Marrero C, Magnano L, Palomera L, Jarque I, Coria E, Rodriguez A, Martín A, López-Guillermo A, Salar A, Lahuerta JJ; GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) cooperative study group. Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma. Cancer Med. 2017 Dec;6(12):2766-2774. doi: 10.1002/cam4.1217. Epub 2017 Oct 26. PMID: 29076254; PMCID: PMC5727300.

2016

Cabrero M, Martin A, Briones J, Gayoso J, Jarque I, López J, Grande C, Heras I, Arranz R, Bernal T, Perez-Lopez E, López-Godino O, Conde E, Caballero D. Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial. Biol Blood Marrow Transplant. 2017 Jan;23(1):53-59. doi: 10.1016/j.bbmt.2016.10.003. Epub 2016 Oct 19. PMID: 27771496.

Martín A, Redondo AM, Dlouhy I, Salar A, González-Barca E, Canales M, Montes-Moreno S, Ocio EM, López-Guillermo A, Caballero D; Spanish Group for Lymphomas and Autologous Bone Marrow (GELTAMO). Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group. Br J Haematol. 2016 Apr;173(2):245-52. doi: 10.1111/bjh.13945. Epub 2016 Feb 5. PMID: 26847165.

Martínez C, Jorge AS, Pereira A, Moreno M, Núñez J, Gayoso J, Gonzalez- Medina J, Revilla N, Sampol A, Domingo-Domenech E, de la Cruz F, Morales A, Rodriguez-Salazar MJ, Valiente S, Pérez-Ceballos E, de Oteyza JP, García-Sanz R; Hodgkin Lymphoma Subcommittee of Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO). Comorbidities, not age, are predictive of survival after autologous hematopoietic cell transplantation for relapsed/refractory Hodgkin's lymphoma in patients older than 50 years. Ann Hematol. 2017 an;96(1):9-16. doi: 10.1007/s00277-016-2832-6. Epub 2016 Oct 18. PMID: 27752822.

González-Barca E, Canales MA, Salar A, Ferrer S, Domingo-Domenech E, Vidal MJ, Grande C, Bargay J, Gardella S, Oriol A, Briones J, García-Frade J, Bello JL, Sánchez-Blanco JJ, Peñalver FJ, Tomás JF, Asensio A, López A, Caballero D; GELTAMO Group (Grupo Español de Linfoma y Trasplante de Médula Ósea). Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First- Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients. Acta Haematol. 2016;136(2):76-84. doi: 10.1159/000444625. Epub 2016 Mayo 18. PMID: 27188649.

González-Barca E, Canales M, Salar A, Ferreiro-Martínez JJ, Ferrer-Bordes S, García-Marco JA, Sánchez-Blanco JJ, García-Frade J, Peñalver J, Bello-López JL, Sancho JM, Caballero D; GELTAMO group. Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial. Ann Hematol. 2016 Mayo;95(6):893-9. doi: 10.1007/s00277-016-2648-4. Epub 2016 Mar 30. PMID: 27025508; PMCID: PMC4853453.

Martínez C, Díaz-López A, Rodriguez-Calvillo M, García-Sanz R, Terol MJ, Pérez-Ceballos E, Jiménez MJ, Cantalapiedra A, Domingo-Domenech E, Rodriguez MJ, Sampol A, Espeso M, López FJ, Briones J, García JF, Sureda A; Hodgkin Lymphoma Subcommittee of Spanish Group of Lymphoma Bone Marrow Transplantation(GELTAMO). Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy. Br J Haematol. 2016 Sep;174(6):859-67. doi: 10.1111/bjh.14133. Epub 2016 Mayo 17. PMID: 27185197.

2015

2014

Pardal E, Coronado M, Martín A, Grande C, Marín-Niebla A, Panizo C, Bello JL, Conde E, Hernández MT, Arranz R, Bargay J, González-Barca E, Pérez-Ceballos E, Montes-Moreno S, Caballero MD. Intensification treatment based on early FDG- PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial. Br J Haematol. 2014 Nov;167(3):327-36. doi: 10.1111/bjh.13036. Epub 2014 Jul 28. PMID: 25066542.

Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntañola A, Canales M, Bello JL, Sancho JM, Tomás JF, Rodríguez MJ, Peñalver FJ, Grande C, Sánchez-Blanco JJ, Palomera L, Arranz R, Conde E, García M, García JF, Caballero D, Montalbán C; Grupo Español de Linfomas/Trasplante de Médula Ósea (GELTAMO). First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2014 Dec;1(3):e104-11. doi: 10.1016/S2352-3026(14)00021-0. Epub 2014 Nov 19. PMID: 27029228.

Montes-Moreno S, Batlle A, de Villambrosía SG, Sánchez-Espiridión B, Cereceda L, González-Barca E, Purroy N, Pardal E, Martín A, Grande C, Mazorra F, Insunza A, Quero C, Aguiar D, Cruz MA, Rueda A, Llanos M, Codina JG, Arroyo FR, Caballero D, Conde E, López A, Provencio M, Piris M. Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis. Haematologica. 2014 Aug;99(8):e138-41. doi: 10.3324/haematol.2014.104976. Epub 2014 Apr 24. PMID: 24763400; PMCID: PMC4116846.

Briones J, Novelli S, García-Marco JA, Tomás JF, Bernal T, Grande C, Canales MA, Torres A, Moraleda JM, Panizo C, Jarque I, Palmero F, Hernández M, González- Barca E, López D, Caballero D; Grupo Español de Linfomas y Trasplante Autologo de Médula Ósea (GELTAMO). Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. Haematologica. 2014 Jul;99(7):e126. doi: 10.3324/haematol.2014.108308. PMID: 24986878; PMCID: PMC4077101.

2013

Arranz R, García-Noblejas A, Grande C, Cannata-Ortiz J, Sánchez JJ, García- Marco JA, Aláez C, Pérez-Calvo J, Martínez-Sánchez P, Sánchez-González B, Canales MA, Conde E, Martín A, Arranz E, Terol MJ, Salar A, Caballero D. First- line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate- cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group. Haematologica. 2013 Oct;98(10):1563-70. doi: 10.3324/haematol.2013.088377. Epub 2013 Jun 10. PMID: 23753021; PMCID: PMC3789461.

Caballero D, Campo E, López-Guillermo A, Martín A, Arranz-Sáez R, Giné E, López A, González-Barca E, Canales MÁ, González-Díaz M, Orfao A. Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group. Ann Hematol. 2013 Sep;92(9):1151-79. doi: 10.1007/s00277-013-1783-4. Epub 2013 Mayo 29. PMID: 23716187.

Briones J, Novelli S, García-Marco JA, Tomás JF, Bernal T, Grande C, Canales MA, Torres A, Moraleda JM, Panizo C, Jarque I, Palmero F, Hernández M, González- Barca E, López D, Caballero D; GELTAMO. Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. Haematologica. 2014 Mar;99(3):505-10. doi: 10.3324/haematol.2013.093450. Epub 2013 Oct 25. PMID: 24162789; PMCID: PMC3943314.

González-Barca E, Canales M, Cortés M, Vidal MJ, Salar A, Oriol A, Bargay J, Bello JL, Sánchez JJ, Tomás JF, Donato E, Ferrer S, Caballero D; GELTAMO (Grupo Español de Linfoma y Trasplante de Médula Ósea). Predictive value of interim ¹?F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment. Nucl Med Commun. 2013 Oct;34(10):946-52. doi: 10.1097/MNM.0b013e328363c695. PMID: 23880897.

Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group. Ann Hematol. Caballero D, Campo E, López-Guillermo A, Martín A, Arranz-Sáez R, Giné E, López A, González-Barca E, Canales MA, González-Díaz M, Orfao A. 2013 Mayo 29. [Epub ahead of print].

Arranz R, García-Noblejas A, Grande C, Cannata-Ortiz J, Sánchez JJ, García-Marco JA, Aláez C, Pérez-Calvo J, Martínez-Sánchez P, Sánchez-González B, Canales MA, Conde E, Martín A, Arranz E, Terol MJ, Salar A, Caballero D. First line treatment with rituximab- Hyper-CVAD alternating with rituximab- Methotrexate- Cytarabine and followed by consolidation with 90Y-Ibritumomab-Tiuxetan in patients with mantle cell lymphoma. Results of a phase 2 pilot multicenter trial from the GELTAMO group. Haematologica. 2013 Jun 10. [Epub ahead of print].

Alcoceba M, Sebastián E, Marin LA, Balanzategui A, Sarasquete ME, Chillon MC, Jiménez C, Puig N, Corral R, Pardal E, Grande C, Bello JL, Albo C, de la Cruz F, Panizo C, Martín A, González-Barca E, Caballero MD, San Miguel JF, García-Sanz R, González M. HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma. Blood 2013 (in press).

2011

2010

2008

Martín A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, Andreu R, Salar A, García-Sanchez P, Vázquez L, Nistal S, Requena MJ, Donato EM, González JA, León A, Ruiz C, Grande C, González-Barca E, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO Cooperative Group). R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica. 2008 Dec;93(12):1829-36. doi: 10.3324/haematol.13440. Epub 2008 Oct 22. PMID: 18945747.

Rodríguez J, Conde E, Gutiérrez A, García JC, Lahuerta JJ, Varela MR, Pérez C, Albo C, Caballero MD. Primary mediastinal large cell lymphoma (PMBL): frontline treatment with autologous stem cell transplantation (ASCT). The GEL- TAMO experience. Hematol Oncol. 2008 Sep;26(3):171-8. doi: 10.1002/hon.858. PMID: 18432630.

Sancho JM, Morgades M, Arranz R, Fernández-Abellán P, Deben G, Alonso N, Blanes M, Rodríguez MJ, Nicolás C, Sánchez E, Fernández de Sevilla A, Conde E, Ribera JM; QUIT Study (PETHEMA, GELTAMO and GOTEL Groups). Practice of central nervous system prophylaxis and treatment in acute leukemias in Spain. Prospective registry study. Med Clin (Barc). 2008 Oct 4;131(11):401-5. doi: 10.1157/13126214. PMID: 18928719.

Sancho JM, Morgades M, Alonso N, Deben G, Fernández de Sevilla A, Vázquez L, Nicolás C, García Vela JA, Arranz R, Abella E, Canales MA, Miralles P, Sánchez E, Hermosilla M, Conde E, Rueda A, Ribera JM; investigators of QUIT Study (PETHEMA, GELTAMO and GOTEL Groups). Prospective study on the practice of central nervous system prophylaxis and treatment in non-Hodgkin's lymphoma in Spain. Med Clin (Barc). 2008 Oct 11;131(12):441-6. doi: 10.1157/13126952. PMID: 18928733.

Martín A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, Andreu R, Salar A, García-Sanchez P, Vázquez L, Nistal S, Requena MJ, Donato EM, González JA, León A, Ruiz C, Grande C, González-Barca E, Caballero MD. On behalf of the ‘Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea’ (GEL/TAMO cooperative group). R-ESHAP as salvage therapy for patients with relapsed or refractory Diffuse Large B-cell Lymphoma: Influence of prior exposure to rituximab on outcome (a GEL/TAMO study). Haematologica 2008; 93: 1829-36.

Martín A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, Andreu R, Salar A, García-Sanchez P, Nistal S, Requena MJ, Donato EM, González JA, León A, Ruiz C, Grande C, Caballero MD. On behalf of the ‘Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea’ (GEL/TAMO cooperative group). R-ESHAP as salvage therapy for patients with relapsed or refractory Diffuse Large B-cell Lymphoma: Influence of prior exposure to rituximab on outcome (a GEL/TAMO study). Ann Oncol 2008; 19 (suppl 4): S149, abstr 216.

Matutes E, Oscier D, Montalban C, Beger F, Callet-Bauchu E, Dogan A, Felman P, Franco V, Iannitto E, Mollejo M, Tapadaki T, Remstein ED, Salar A, Dolé F, Stamapoulos K, Thieblemont C, Traverse-Gjehen A, Wotherspoon A, Coiffier B, Piris MA. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia, 2008; 22; 487-495

Santon A, García-Cosio M, Bellosillo B, Rodriguez P, Cristobal E, Serrano S, Besses C, A Persistent monoclonality after histological remission in gastric mucosa-associated lymphoid tissue lymphoma treated with chemotherapy and/or surgery: influence of t(11;18)(q21;q21)braira V, Salar A, Montalban C. Leukemia & Lymphoma, 2008; 49; 1561-1522

2007

Rodríguez J, Conde E, Gutiérrez A, Arranz R, Gandarillas M, Leon A, Ojanguren J, Sureda A, Carrera D, Bendandi M, Moraleda J, Ribera JM, Albo C, Morales A, García JC, Fernández P, Cañigral G, Bergua J, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol. 2007 Apr;78(4):290-6. doi: 10.1111/j.1600-0609.2007.00815.x. PMID: 17378891.

Rodríguez J, Conde E, Gutiérrez A, Lahuerta JJ, Arranz R, Sureda A, Zuazu J, Fernández de Sevilla A, Bendandi M, Solano C, León A, Varela MR, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea, Spanish Lymphoma/Autologous Bone Marrow Transplant Study Group. The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica. 2007 Aug;92(8):1067-74. doi: 10.3324/haematol.11173. Epub 2007 Jul 20. PMID: 17640855.

Rodríguez J, Conde E, Gutiérrez A, Arranz R, León A, Marín J, Bendandi M, Albo C, Caballero MD; 'Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea' (GEL-TAMO). Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol. 2007 Jul;79(1):32-8. doi: 10.1111/j.1600-0609.2007.00856.x. PMID: 17598836.

Ribera JM, Oriol A, Morgades M, González-Barca E, Miralles P, López- Guillermo A, Gardella S, López A, Abella E, García M; PETHEMA, GELTAMO, GELCAB and GESIDA Groups. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol. 2008 Feb;140(4):411-9. doi: 10.1111/j.1365-2141.2007.06943.x. Epub 2007 Dec 19. PMID: 18162120.

Arranz R, Conde E, Grande C, Mateos MV, Gandarillas M, Albo C, Lahuerta JJ, Fernández-Rañada JM, Hernández MT, Alonso N, García Vela JA, Garzón S, Rodríguez J, Caballero D; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL-TAMO). Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group. Eur J Haematol. 2008 Mar;80(3):227-35. doi: 10.1111/j.1600-0609.2007.01020.x. Epub 2007 Dec 18. PMID: 18088400.

A Martín, E Conde, E González Barca, MA Canales, G Deben, R Andreu, A Salar, P García Sánchez, S Nistal, MJ Requena, EM Donato, JA González, A León, C Ruiz, C Grande, R Arranz, S Durán, S Ortegón, JN Rodríguez, V Sandoval, MA Andreu, T Bernal, MT Hernández, MD Caballero. Grupo Español de Linfomas GEL-TAMO. R-ESHAP como régimen de rescate en pacientes con Linfoma B Difuso de Células Grandes: Estudio observacional retrospectivo sobre su eficacia y toxicidad. Haematologica 2007, 92, Extraordinario 2: C-079.

Reyes Arranz, Eulogio Conde, Carlos Grande, Maria Victoria Mateos, Marco Gandarillas, Carmen Albo, Juan J. Lahuerta, José M. Fernández-Rañada, Miguel T. Hernández, Natalia Alonso, José A. García Vela, Sebastián Garzón, José Rodríguez, Dolores Caballero, on behalf of the Grupo Español de Linfomas ? Trasplante Auto´ logo de Médula Ósea (GEL–TAMO)Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/ autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL–TAMO Study Group. European Journal of Haematology. Accepted for publication: 1 Diciembre 2007

J. Rodríguez, E. Conde, A. Gutiérrez, R. Arranz, A. León, J. Marín, M. Bendandi, C. Albo, M.D. Dolores. On behalf of the Grupo Español de Linfomas/Trasplante Autólogo de Médula ösea. The results of consolidation with autologous stem-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol. January 2007

J. Rodríguez, E. Conde, A. Gutiérrez, R. Arranz, M. Gandarillas, A. León, J. Ojanguren, A. Sureda, D. Carrera, M. Bendandi, J. Moraleda, J.Mª Ribera, C. Albo, A. Morales, J.C. García, P. Fernández, G. Cañigral, J. Bergua, Mª D. Caballero. On behalf of the Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO Spanish lymphoma/autologous marrow transplant study group). Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. The GELTAMO experience. European Journal of Haematology, 78, 290-296, 2007

2005

Serrano D, Carrión R, Balsalobre P, Miralles P, Berenguer J, Buño I, Gómez- Pineda A, Ribera JM, Conde E, Díez-Martín JL; Spanish Cooperative Groups GELTAMO and GESIDA. HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. Exp Hematol. 2005 Apr;33(4):487-94. doi: 10.1016/j.exphem.2004.12.008. PMID: 15781340.

Sureda A, Constans M, Iriondo A, Arranz R, Caballero MD, Vidal MJ, Petit J, López A, Lahuerta JJ, Carreras E, García-Conde J, García-Laraña J, Cabrera R, Jarque I, Carrera D, García-Ruiz JC, Pascual MJ, Rifón J, Moraleda JM, Pérez- Equiza K, Albó C, Díaz-Mediavilla J, Torres A, Torres P, Besalduch J, Marín J, Mateos MV, Fernández-Rañada JM, Sierra J, Conde E; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea Cooperative Group. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol. 2005 Apr;16(4):625-33. doi: 10.1093/annonc/mdi119. Epub 2005 Feb 28. PMID: 15737986.

D. Serrano, R. Carrión, P. Balsalobre, P. Miralles, J. Berenguer, I. Buño, A. Gómez-Pineda, J.Mª Ribera, E. Conde, J.L. Díez-Martín on behalf of Spanish Cooperative Groups GELTAMO and GESIDA. HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. Experimental Hematology. 2005; 33: 487-494.

A.Sureda, M. Constans, A. Iriondo, R. Arranz, M.D. Caballero, M.J. Vidal, J. Petit, A. López, J.J. Lahuerta, E. Carreras, J. García-Conde, J. García-Laraña, R. Cabrera, I. Jarque, D. Carrera, J.C. García-Ruiz, M.J. Pascual, J. Rifón, J.M. Moraleda, K. Pérez-Equiza, C. Albó, J. Díaz-Mediavilla, A. Torres, J. Besalduch, J. Marín, M.V. Mateos, J.M. Fernández-Rañada, J. Sierra, E. Conde for The Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO) Cooperative Group. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol. Feb. 2005;

J. Rodríguez, M. Caballero, A. Gutierrez, J. Marín, R. Arranz, J. Lahuerta, J. Sierra, A. López-Guillermo, A.. Sureda, E. Carrerras, A. Leon, A. Fernández de Sevilla, J. Zuazu, M. Sanz, G. García-Laraña, M. Bendandi, R. Varela, M Gandarillals, J. San Miguel, E. Conde, “Long-term follow-up of autologous stem cell transplantation (ASCT) in patients with peripheral T-cell lymphoma (OTCL)”: the Spanish Lymphoma Cooperative Group (GEL-TAMO) experience Ann Oncol 2005 16 (5): 56 v

J. Rodríguez, M. Caballero, A. Gutierrez, J. Marín, R. Arranz, J. Lahuerta, J. Sierra, A. López-Guillermo, A.. Sureda, E. Carrerras, A. Leon, A. Fernández de Sevilla, J. Zuazu, M. Sanz, G. García-Laraña, M. Bendandi, R. Varela, M Gandarillals, J. San Miguel, E. Conde, Hematology-Oncology, On behalf of Spanish Lymphoma Cooperative Group (GEL-TAMO) Spain. “Front-line autologous stem cell transplantation (ASCY) improves the outcome of peripheral T-cell lymphoma (OTCL) in first remissión patient presenting with unfavourable prosgnostic factor” . Ann Oncol 2005 16 (5)

M.D. Caballero, R. Arranz, J. Rodríguez, M.L. Gutiérrez, C. Grande, M. Gandarillas, C. Albo, S. Garzón, M.T. Hernández, J.A. García Vela, P. Fernández Abellán, J.L. Bello, M.L. Amigo and E. Conde. On behalf on the GEL/TAMO Group. Treatment Stratification According to Early Response to Mega-CHOP, Based on CT and Gallium67 Scan (G67S) with or without IFE Salvage Therapy Followed by Peripheral Autologous Stem Cell Transplant (PBSCT) in Patient with Poor Prognosis Aggressive Lymphoma. A Preliminary Report from a Porspective GELTAMO Trial. Ann Oncol 2005, 16 (5): v184.

2004

Rodriguez J, Caballero MD, Gutierrez A, Solano C, Arranz R, Lahuerta JJ, Sierra J, Gandarillas M, Perez-Simon JA, Zuazu J, Lopez-Guillermo A, Sureda A, Carreras E, Garcia-Laraña J, Marin J, Garcia JC, Fernandez De Sevilla A, Rifon J, Varela R, Jarque I, Albo C, Leon A, SanMiguel J, Conde E. Autologous stem- cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience. Ann Oncol. 2004 Oct;15(10):1504-9. doi: 10.1093/annonc/mdh391. PMID: 15367411.

Rodríguez, M.D. Caballero, A. Gutiérrez, C. Solano, R. Arranz, J.J. Lahuerta, J. Sierra, M. Gandarillas, J.A. Pérez-Simón, J. Zuazu, A. López-Guillermo, A. Sureda, E. Carreras, J. García-Laraña, J. Marin, J.C. García, A. Fernández Sevilla, J. Rifón, R. Varela, on behalf of the GEL/TAMO Spanish Group.Autologous stem-cell transplantation in diffuse large B-cell-non-Hodgkin’s lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience. Ann Oncol. 2004; 15: 1504-1509

M. Constans, A. Sureda, R. Arranz, MD Caballero, JJ. Lahuerta, J. Hernández-Boluda, M. Vidal, G. García-Laraña, J. Riffón, J. Ribera, P. Fernández-Abellán, J. Moraleda, M. Bernal, M. Mateos, M. Martín-Mateos, R. Córdoba, J. García-Conde, J. Sierra, E. Conde, Grupo GEL/TAMO “Prognostic factors effecting long-term outcome in patients with Hodgkin Lymphoma who relapse after autologous stem cell transplantation” Bone Marrow Transplant 2004; 33 (1): 6.

J. L. Diez-Martín, P. Balsalobre, P Miealles, A Gómez-Pineda, R. Carrión, I. Buño, S Resino, E. Conde, JM Ribera, D. Serrano, J. Beremguer GEL/TAMO and GESDIDA“Efficacy of autologous stem cell transplant in aids-relalted lymphoma patients” Bone Marrow Transplant 2004; 33 (1): 35.

M. Constans, A- Sureda, R. Arranz, MD. Caballero, JJ. Lahuerta, JC. Hernández-Boluda, MJ Vidal, J. García.Laraña, J. Rifón, JM Ribera, P. Fernández-Abellán, JM Moraleda, MR Bernal, MV Mateos, M Martín-Mateos, R. Córdoba, J. García-Conde, J. Sierra, E. Conde por Sapnish Cooperative (GEL/TAMO) “Secondary Malignancies after autologous Stem Cell trasplantation for Hodgkin´s Lymphoma: Incidence and Analysis Risk Factors” Blood. 2004; 104, 11 (1): 21 a

M. Constans, A- Sureda, R. Arranz, MD. Caballero, JJ. Lahuerta, JC. Hernández-Boluda,MJ Vidal, J. García.Laraña, J. Rifón, JM Ribera, P. Fernández-Abellán, JM Moraleda, MR Bernal, MV Mateos, M Martín-Mateos, R. Córdoba, J. García-Conde, J. Sierra, Eulogio Conde por Sapnish Cooperative (GEL/TAMO)“Pronostic Factor and Long-Term Outcome for Patients with Hodgkin´s Lymphoma Who Relapse after an Autologous Stem Cell Transplantation” Blood. 2004; 104, 11 (1): 458-459ª

M. Constans, A. Sureda, MD Caballero, JJ. Lahuerta, JC Hernández-Boluda, MJ Vidal, J. Garcia-Laraña, J. Rifón, JM. Ribera, P. Fernández-Abellán, JM Moraleda, MT. Bernal, MV. Mateos, M. Martín-Mateos, R. Córdoba, J. Sierra y E. Conde (GEL/TAMO) “Segundas neoplasias (SN) Post-Trasplante autólogo de progenitores hematopoyéticos (TASPE) en el linfoma de Hodgkin (LH) Incidencia y Factores de riesgo” Haematológica. 2004; 89 (2): 36

ML. Gutierrez, D. Caballero, M. Gandarillas, C. Grande, R. Arranz, C. Albo, S. Garzón, M. Hernández, P. Fernández Abellán, H. Cano, JL Bello, JA García Vela, C. Panizo, J. García Marzo, J. García Laraña, A. de Dios, J. Bergúa, A. Iriondo y E. Conde (GEL/TAMO)“Megachop+IFE seguido de TACPH en pacientes con LNH de mal pronóstico: Resultados preliminares del estudio prospectivo del grupo GELTAMO” Haematológica. 2004; 89 (2): 54

- M. Constans, A. Sureda, R. Arranz, MD Caballero, JJ. Lahuerta, JC. Hernández-Boluda, MJ Vidal, J. Garcia-Laraña, J. Rifón, JM. Ribetas, P. Fernández-Abellán, , JM Moraleda, MT. Bernal,, MV. Mateos, M. Martín-Mateos, R. Córdoba, J. García-Conde, J. Sierra y E. Conde (GEL/TAMO)“Recaída Post-trasplante autólogo de progenitores hematopoyéticos (TASPE) en el linfoma de Hodgkin (LH) Resultados a largo plazo y factores pronósticos” Haematológica. 2004; 89 (2): 58

2003

Rodríguez J, Caballero MD, Gutiérrez A, Marín J, Lahuerta JJ, Sureda A, Carreras E, León A, Arranz R, Fernández de Sevilla A, Zuazu J, García-Laraña J, Rifon J, Varela R, Gandarillas M, SanMiguel J, Conde E. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL- TAMO experience. Ann Oncol. 2003 Dec;14(12):1768-75. doi: 10.1093/annonc/mdg459. PMID: 14630683.

Constans M, Sureda A, Terol MJ, Arranz R, Caballero MD, Iriondo A, Jarque I, Carreras E, Moraleda JM, Carrera D, León A, López A, Albó C, Díaz-Mediavilla J, Fernández-Abellán P, García-Ruiz JC, Hernández-Navarro F, Mataix R, Petit J,P Pascual MJ, Rifón J, García-Conde J, Fernández-Rañada JM, Mateos MV, Sierra J, Conde E; GEL/TAMO Cooperative Group. Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome. Ann Oncol. 2003 Mayo;14(5):745-51. doi: 10.1093/annonc/mdg206. PMID: 12702529.

Caballero MD, Pérez-Simón JA, Iriondo A, Lahuerta JJ, Sierra J, Marín J, Gandarillas M, Arranz R, Zuazu J, Rubio V, Fernández de Sevilla A, Carreras E, García-Conde J, García-Laraña J, Grande C, Sureda A, Vidal MJ, Rifón J, Pérez- Equiza C, Varela R, Moraleda JM, García Ruíz JC, Albó C, Cabrera R, San Miguel JF, Conde E. High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol. 2003 Jan;14(1):140-51. doi: 10.1093/annonc/mdg008. PMID: 12488306.

Rodriguez J, Caballero MD, Gutierrez A, Gandarillas M, Sierra J, Lopez- Guillermo A, Sureda A, Zuazu J, Marin J, Arranz R, Carreras E, Leon A, De Sevilla AF, San Miguel JF, Conde E; GEL/TAMO Spanish Group. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. Haematologica. 2003 Dec;88(12):1372-7. PMID: 14687990.

M. Constans, A. Sureda, M.J. Terol, R. Arranz, M.D. Caballero, A. Iriondo, I. Jarque, E. Carreras, J.M. Moraleda, D. Carrera, A. León, A. López, C. Albo, J. Díaz-Mediavilla, P. Fernández-Abellán, J.C. García-Ruiz, F. Hernández-Navarro, R. Mataix, J. Petit, M.J. Pascual, J. Rifón, J. García-Conde, J.M. Fernández-Rañada, M.V. Mateos, J. Sierra & E. Conde. On behalf of the GEL/TAMO Cooperative Group. Autologous stem cell transplantation for primary refractory Hodgkin’s disease: results and clinical variables affecting outcome. Annals of Oncology 2003; 14: 745-51

M.D. Caballero, J.A. Pérez-Simón, a. Iriondo, J.J. Lahuerta, J. Sierra, J. Marín, M. Gandarillas, R. Arranz, J. Zuazu, V. Rubio, A. Fernández de Sevilla, E. Carreras, J. García-Conde, J. García-Laraña, C. Grande, A. Sureda, M.J. Vidal, J. Rifón, C. Pérez-Equiza, R. Varela, J.M. Moraleda, J.C. García Ruiz, C. Albo, R. Cabrera, J.F. San Miguel & E. Conde. On behalf of the Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea Spanish Cooperative Group. High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL/TAMO Spanish Cooperative Group.Annals of Oncology 2003; 14: 140-51 (ISSN:0923-7534) Edt.D.J. Kerr- Rd.

Juan José Lahuerta, Carlos Grande, Joaquín Martínez-Lopez, Javier de la Serna, Rosa Toscano, María Cruz Ortiz, Santiago Larregla, Eulogio Conde, Andrés Insunza, José David Gonzalez-San Miguel, Juan Bargay, Rafael Cabrera, Juan Carlos García-Ruiz, Carmen Albó, Luis García-Alonso, Fernando Solano, Pilar Vivancos, Angel León and Jesús San Miguel. Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Español de Síndromes Linfoproliferativos /Trasplante Autólogo de Médula Ósea phase II trial. Br J Hemtol 2003; 120:296-303

J. Rodríguez, MD Caballero, A. Gutierrez, A. Marín, JJ Lahuerta, E. Carreras, A. León, R. Arranz, A. Fernández de Sevilla, J. Zuazu, J. García-Laraña, J. Rifón, R. Varela, M Gandarillas, J San Miguel, E. Conde. High dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma : The GEL-TAMO experience. Ann Oncology 2003; 14:1768-75 (ISSN:0923-7534) Edt.D.J. Kerr- Rd. Board –Oxford

J. Rodríguez, MD Caballero, A. Gutierrez, M Gandarillas, J. Sieirra, A. López-Guillermo, A. Sureda, J Zuazu, J Marín, R. Arranz, E. Carreras, A León, AF de Sevilla, JF San Miguel, E. Conde.High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. Hematológica 2003; 88:1372-77

2002

2001

Salar A, Sierra J, Gandarillas M, Caballero MD, Marín J, Lahuerta JJ, García-Conde J, Arranz R, León A, Zuazu J, García-Laraña J, López-Guillermo A, Sanz MA, Grañena A, García JC, Conde E; GEL/TAMO Spanish Cooperative Group. Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens. Bone Marrow Transplant. 2001 Feb;27(4):405-12. doi: 10.1038/sj.bmt.1702795. PMID: 11313670.

A. Sureda, R. Arranz, A. Iriondo, E. Carreras, JJ. Lahuerta, J. García-Laraña, I. Jarque, MD. Caballero, C. Ferrà, A. López, J. García-Laraña, R. Cabrera, D. Carrera, MD. Ruiz-Romero, A. León, J. Rifón, J. Díaz-Mediavilla, R. Mataix, M. Morey, JM. Moraleda, A. Altés, A. López-Guillermo, J. de la Serna, JM. Fernández-Rañada, J. Sierra, E. Conde for the Spanish Cooperative Group GELTAMO. Autologous Stem-Cell Transplantation for Hodgkin’s Disease: Results and Prognostic Factors in 494 patients from the Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea Spanish Cooperative Group. Journal of Clinical Oncology, Marzo 2001; Vol 19, No 5: pp 1395-1404.

Caballero D, Pérez-Simón J.A, García-Laraña J, Gandarillas M, Marín J, Lahuerta JJ, Arranz R, Rubio V, García-Conde J, Zuazu J, Vázquez L, Montserrat E, Grañena A, Sanz MA, Mataix R, Maldonado J, Rifón J, Sierra J, Carrera D, Moraleda JM, Conde E. High dose therapy in large cell lymphoma: analysis of prognostic factors in 452 patients of GEL-TAMO Restry. Bone Marrow Transplant 2001; 27: S14.

Guglielmi C, Gómez F, Conde E. Prognostic evaluation in adults with diffuse large B-cell lymphoma treated with autologous stem cell transpalntation at first sensitive relapse. Bone Marrow Transplant 2001; 27: S259-S260.

Rodriguez J, Caballero D, Solano C, Lahuerta JJ, Arranz R, Sureda A, Marín J, García-Laraña J, López-Guillermo A, San Miguel J, Conde E. High-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) in patients with primary refractory aggressive non-Hodgkin´s lymphoma. Bone Marrow Transplant 2001; 27: S260-S261.

Sureda A, Arranz R, García-Conde J, Caballero D, Iriondo A, Jarque I, López-Guillermo A, León A, Carrera D, López A, Ruiz MD, Díaz-Mediavilla J, Grañena A, Hernández-Navarro F, Mataix R, Moraleda JM, Albo C, Pérez-Equiza K, Sierra J, Fernández-Rañada JM, Solano C, Regadera A, Carreras E, Conde E. High dose therapy with autologous stem cell transplantation in primary refractory Hodgkin´s disease: Experience of the Spanish GEL/TAMO group. Bone Marrow Transplant 2001; 27: S269.

Salar A, Sierra J, Gandarillas M, Caballero D, Marín J, Lahuerta JJ, García-Conde J, Arranz R, León A, Zuazu J, García-Laraña J, López-Guillermo A, Sanz MA, Grañena A, García JC, Conde E for the GEL/TAMO Spanish Cooperative Group. Autologous stem cell transplantation for clinically agressive non-Hodgkin´s lymphoma: the role of preparative regimens. Bone Marrow Transplant 2001; 27:405–412.

Marco F, Caballero D, Arranz R, Lahuerta JJ, Sureda A, García-Laraña J, Gandarillas M, Cabrera R, León A, Muruzabal MJ, Zuazu J, Albo C, Bermúdez A, Marín J, Moraleda JM, Varela MR, Carreras E, Fernández-Sevilla A, Rifón J, Campo C, Pascual MJ, García JC, García-Conde J, Carrera D, Pérez-Eqiuza K, Bello JL, Conde E. Secondary neoplasms after autologous transplantation in patients with lymphoma. Blood 2001; 98:369

Rodriguez J, Caballero D, Gutierrez A, Sierra J, López-Guillermo A, Marín J, Sarra J, Lahuerta JJ, Rifón J, Conde E. Results of high dose chemotherapy and autologous stem cell transplantation in patients with pheripheral T-cell lymphoma. The Spanish Lymphoma Cooperative Group experience (GEL/TAMO). Blood 2001; 98:680

2000

A. Salar, J. Sierra, D. Caballero, J. Marín, JJ Lahuerta, J. García-Conde, R. Arranz, A. León, J. Zuazu, J. García-Laraña, JC. García, MA. Sanz, A. Grañena, E. Montserrat, E. Conde. The GEL/TAMO Spanish Cooperative Group. Autologous stem cell transplantation for clinically aggressive non-Hodkin’s Lymphoma: The role of preparative regimen. The Hematology Journal, Junio 2000; 1 (supp 1):253.

Guglielmi C, Gomez F, Conde E. Factors influencing the outcome of autologous stem cell transplant at first sensitive relapse in 247 adults with diffuse large B-cell lymphoma. Blood 2000, 96:794a.

Conde E, García-Conde J, Caballero D, Arranz R, Sierra J, Gandarillas M, García JM, Vidal MJ, Lahuerta JJ, López-Guillermo A, Albo C, García-Laraña J, Marco F, Varela MR, Rifón J, Zuazu J, Fernández-Sevilla A, Campo C. Autologous stem cell transplantation (ASCT) for mediastinal large B-cell lymphoma with sclerosis (MLBCL). Blood 2000, 96:796a.

Sanz Rodríguez C, Sanchez A, Rodríguez F, Gandarillas M, Conde E, Arranz R. Chemotherapy plus interferon-"-2b vs. high-dose therapy for response consolidation in low grade non-hodgkin’s lymphoma: Results of a retrospective case control study. On behalf of the GEL/TAMO Spanish cooperative Group and the LNH-PRO Study Group. Spain. Blood 2000; 96:791a.

A. Sureda, R. Arranz, R. Cabrera, J. García Laraña, A. Iriondo, JJ. Lahuerta, A. León, A. López, R. Mataix, JM. Moraleda, MD Ruiz-Romero, E. Carreras, J. García-Conde, I. Jarque, MD. Caballero, C. Ferrà, D. Carrera, J. Rifón, J. Díaz.-Mediavilla, M. Morey, A. López-Guillermo, J. De la Serna, JM. Fernández Rañada, J. Sierra, E. Conde for the GEL/TAMO Spanish cooperative group. Secondary Malignancies risk after Autologous stem cell transplantation (ASCT) for Hodgkin`s disease (HD). A retrospective analysis from the GEL/TAMO. En Bone Marrow Transplantation 2000; 25 (supp 1): S42.

Conde por el GELTAMO. Mega-Chop frente a trasplante autólogo de células progenitoras hematopoyéticas en pacientes con Linfoma No Hodgkin de alto riesgo. Methods Find Exp Clin Pharmacol 2000, Vol 22(1): 87-89.

1999

E. Conde, J. Zuazu, A. López-Guillermo, J. García-Laraña, R. Arranz, J. Sierra, JJ. Lahuerta, D. Caballero, J. García-Conde, M. Gandarillas, MJ. Vidal, A. Grañena, J. Rifón, A. Torres, F. Hernández Navarro, JL. Bello, A. Iriondo. Autologous stem cell transplantation for lymphoblastic lymphoma. En Blood 1999; 94 (Suppl 1): 477a.

A. Sureda, R. Arranz, A. Iriondo, E. Carreras, J. Zuazu, JJ. Lahuerta, et al. High dose therapy with autologous stem cell transplantation in hodgkin's disease in first relapse: Experience of the Spanish Gel/tamo group. En Haematologica 1999; 84 (abst book): 1174.

E. Conde, JJ. Lahuerta, J. Sierra, R. Arranz, E. Montserrat, D. Caballero, J. García-Conde, M. Gandarillas, V. Rubio, J. Bueno, A. Grañena, J. García-Laraña, MJ. Vidal, D.Carrera, P. Giraldo, JM. Moraleda, J. Maldonado, F. Hernández, P. Vivancos, M. Gutierrez, MR. Varela, S. Larregla, A. Zubizarreta. High-Dose therapy and autologous stem cell transplantation (ASCT) in 210 patients with follicular lymphoma (FL). Annals of Oncology 1999. Volumen (Supl. 3); 10: 75.

MD. Caballero et al. High dose therapy with autologous stem cell support in 366 patients with large cell lymphoma. A retrospective analysis of the GELTAMO Spanish Cooperative Group. Annals of Oncology 1999. Volumen (Supl. 3); 10: 77.

E. Conde, F. Bosch, R. Arranz, D. Caballero, JJ. Lahuerta, J. García-Conde, JM. Fernández-Rañada, A. León, A. Iriondo, J. Besalduch, A. Grañena, D. Carrera, J. Marín, S. Brunet, J. Maldonado, JM. Moraleda, D. Rubio, J. Díaz Mediavilla, P. Vivancos, MA. Piris , E. Montserrat. High-Dose therapy and autologous stem cell transplantation in 56 patients with mantle cell lymphoma. Annals of Oncology 1999. Volumen (Supl. 3); 10: 78.

A. Sureda, R. Arranz, A. Iriondo, E. Carreras, A. López, JJ. Lahuerta, D. Caballero, J. Berlanga, J. García-Conde, D. Carrera, R. Cabrera, J. García-Laraña, J. Maldonado, J. Rifón, J. Díaz-Mediavilla, J. Besalduch, R. Varela, A. León, R. Mataix, JM. Moraleda, C. Herrera, E. Bengoechea, L. Palomera, C. Albo, JD. González, J. Ojanguren, JC. García, JM. Fernández-Rañada, J. Sierra, E.Conde for the GEL/TAMO. Autologous stem cell transplantation (ASCT) in Hodgkin's Disease (HD) after first relapse: Experience of the Spanish GELTAMO Group.Bone Marrow Transplant 1999 (Supl.1) ; 23:S105.

A. Sureda, R. Arranz, A. Iriondo, E. Carreras, JJ. Lahuerta, J. García-Conde, I. Jarque, D. Caballero, C. Ferrà, A. López, J. García-Laraña, R. Cabrera, D. Carrera, J. Maldonado, A. León, J. Rifón, J. Díaz-Mediavilla, R. Mataix, J. Besalduch, JM. Moraleda, A. López-Guillermo, R. Bornstein, JM. Fernández-Rañada, J. Sierra, E.Conde for the GEL/TAMO Spanish Group. Autologous stem cell transplants (ASCT) for Hodgkin's Disease (HD): Results and prognostic factors in 495 patients. Experience of the GELTAMO Spanish Group. Bone Marrow Transplant 1999 (Supl.1) ; 23:S105.

MD. Caballero, J. García-Laraña, M. Gandarillas, J. Marín, JJ. Lahuerta, R. Arranz, V. Rubio, J. García-Conde, J.Zuazu, L. Vazquez, E. Montserrat, A. Grañena, MA. Sanz, R. Mataix, J. Maldonado, J. Rifón, J. Sierra, D. Carrera, JM. Moraleda, JC García, E. Conde. High dose therapy with autologous stem cell support in 366 patients with large cell lymphoma. A retrospective analysis of the GELTAMO Spanish Cooperative Group. Bone Marrow Transplant 1999 (Supl.1) ; 23:S156.

JJ. Lahuerta, E. Conde, J. Sierra, R. Arranz, E. Montserrat, D. Caballero, J. García-Conde, M Gandarillas, V. Rubio, J. Bueno, A. Grañena, LG. Ponte, J. García-Laraña, MJ. Vidal, D. Carrera, D. Rubio-Félix, JM. Moraleda, J. Maldonado, F. Hernández, P. Vivancos, M. Gutierrez, MR. Varela, R. Bornstein, A. Zubizarreta. Autologous stem cell transplantation (ASCT) for Follicular Lymphoma (FL). The Experience of the GELTAMO Spanish Group.Bone Marrow Transplant 1999 (Supl.1) ; 23:S157.

E. Conde, F. Bosch, R. Arranz, D. Caballero, JJ. Lahuerta, J. García-Conde, J. Sierra, M. Gandarillas, JM. Fernández-Rañada, A. León, A. Iriondo, J. San Miguel, J. Besalduch, A. Grañena, D. Carrera, J. Marín, J. Maldonado, JM. Moraleda, D. Rubio-Félix, J. Díaz Mediavilla, J. Zuazu, P. Vivancos, L. Palomera, MA. Piris, E. Montserrat. Autologous stem cell transplantation (ASCT) for Mantle cell Lymphoma (MCL). The Experience of the GELTAMO Spanish Group. Bone Marrow Transplant 1999 (Supl.1) ; 23:S157.

E. Conde (Por el GEL/TAMO): El trasplante de células progenitoras de sangre periférico (TCSP) en los linfomas de Hodgkin y no-Hodgkin. En: Vll Seminario sobre trasplante con células de sangre periférica. Coordinadores: J. Odriozola y D. Caballero. Sangre , Mayooo 1999 (Supl. 1); 44.

1998

1997

Sureda A, Mataix R, Hernández-Navarro F, Jarque I, Lahuerta JJ, Tomás JF, Brunet S, Caballero D, Conde E, León A, Fernández MN, López A, Maldonado J, Bengoechea E, Callís M, Carrera D, García-Conde J, García-Laraña J, Moraleda JM, Morey M, Rifón J, Sierra J, Torres A, Domingo-Albós A. Autologous stem cell transplantation for poor prognosis Hodgkin's disease in first complete remission: a retrospective study from the Spanish GEL-TAMO cooperative group. Bone Marrow Transplant. 1997 Aug;20(4):283-8. doi: 10.1038/sj.bmt.1700886. PMID: 9285542.

JJ. Lahuerta-Palacios, C. Grande, J de la Serna, R. Bornstein, J. Bargay, E. Conde, R. Toscano, MC. Ortiz, JD. González San Miguel, C. Albo, S. Larregla, R. Ayala, J. Besalduch and A. Iriondo (Intr. By JL. Díez). In behalf of the Spanish Cooperative Group GEL/TAMO, Madrid. Spain. High-dose cyclophosphamide, BCNU and VP-16 (CBV) supported with second autologous hemopoietic transplant (Tx) in multiple myeloma (MM) chemosensitive to melphalan 200 mg/m². An interim report.Blood 1997 (Supl. 1); 90, NO 10: 1019.

E. Conde et al.Autologous stem cell transplantation for mantle cell lymphoma. The experience of the GEL/TAMO Spanish Cooperative Group.E. Conde, F. Bosch, R. Arranz, D. Caballero, JJ. Lahuerta, J. García-Conde, JM. Fernández-Rañada, A. León, A. Iriondo, J. Besalduch, A. Grañena, D. Carrera, J. Marín, S. Brunet, J. Maldonado, JM. Moraleda, D. Rubio, J. Díaz Mediavilla, P. Vivancos, MA. Piris and E. Montserrat. Blood 1997 (Supl. 1); 90, NO 10: 1020.

A. Sureda, J. García-Conde, J. Sierra, JF.Tomás, I. Jarque, E. Conde, D. Caballero, A. León-Lara, J. Maldonado, M. Callís, D. Carrera, A. López, R. Mataix, JM. Moraleda, A. Pérez-López, R. Arranz, S. Brunet, E. Montserrat, C. Solano, MA. Sanz and A. Domingo-Albós.Autologous stem cell transplantation in primary refractory Hodgkin's disease: Retrospective analysis of 44 patients from the Spanish GEL/TAMO Cooperative Group.Blood 1997 (Supl. 1); 90, NO 10: 4584.

A. Sureda, R. Mataix, F. Hernández-Navarro, I. Jarque, JJ. Lahuerta, JF. Tomás, S. Brunet, D. Caballero, E. Conde, A. León, MN. Fernández, A. López, J. Maldonado, E. Bengoechea, M. Callís, D. Carrera, J. García-Conde, J. García-Laraña, JM. Moraleda, M. Morey, J. Rifón, J. Sierra, A. Torres, A. Domingo-Albós.Autologous steam cell trasnsplantation for poor prognosis hodgkin's disease in first complete remission: A retrospective study from the Spanish Cooperative Group GEL/TAMO.Bone Marrow Transplant 1997 (Supl. 1); 19:S198.

A. Sureda, R. Mataix, F. Hernández-Navarro, I. Jarque, JJ. Lahuerta, JF. Tomás, S. Brunet, D. Caballero, E. Conde, A. León, MN. Fernández, A. López, J. Maldonado. E. Bengoechea, M. Callís, D. Carrera, J. García-Conde, J. García-Laraña, JM. Moraleda, M. Morey, J. Rifón, J. Sierra, A. Torres, A. Domingo-Albós, for the Spanish Cooperative Group. Autologous steam cell trasnsplantation for poor prognosis hodgkin's disease in first complete remission: A retrospective study from the Spanish GEL/TAMO Cooperative Group.Bone Marrow Transplant 1997; 20:283-288.

A. Sureda, J. García-Conde, J. Sierra, JF. Tomás, I. Jarque, E. Conde, D. Caballero, A. León-Lara, J. Maldonado, M. Callís, D. Carrera, A. López, R. Mataix, JM. Moraleda, A. Pérez-López, R. Arranz, S. Brunet, E. Montserrat, C. Solano, MA. Sanz, A. Domingo-Albós, por el grupo GEL/TAMO. Trasplante Autólogo en progenitores hematopoyéticos (TAPH) en la enfermedad de Hodgkin (EH) primariamente refractaria: Experiencia del grupo GEL/TAMO. Haematologica 1997 (Supl. 2); 82: 322.

E. Conde, F. Bosch, R. Arranz, D. Caballero, JJ. Lahuerta, J. García-Conde, JM. Fernández-Rañada, A. León, A. Iriondo, J. Besalduch, A. Grañena, D. Caballero, J. Marín, S. Brunet, J. Maldonado, JM. Moraleda, D. Rubio, J. Díaz-Mediavilla, P. Vivancos, MA. Piris, E.Montserrat. Trasplante Autólogo de células progenitoras hematopoyéticas en el linfoma de células del manto. Experiencia del Grupo GEL/TAMO. Haematologica 1997 (Supl. 2); 82: 457.

1996

JJ. Lahuerta-Palacios, C. Grande, J. de la Serna, J. Bargay, R. Bornstein, MC. Ortiz, R. Toscano, S. Larregla. High-dose cyclophosphamide, BCNU and VP-16 (CBV) supported with a second autologous hemopoietic transplant (Tx) in multiple myeloma (MM) chemosensitive to melfalan 200 mg/m² (MEL200). First interim report. (Spanish Cooperative Group GEL/TAMO and GETH study). Hematology Units, Hospital "12 de Octubre" (Madrid) and Hospital "Son Dureta (Palma de Mallorca), Spain. Br J Haematol 1996; 93 (Supl. 2):83.

JJ. Lahuerta-Palacios, Javier de la Serna, Angel León, Eulogio Conde, Marco Gandarillas, Mª Jesús Vidal, Dolores Caballero, Reyes Arranz, José Mª Moraleda, Carmen Artacho, Dolores Carrera, Pilar Vivancos, José Luis Bello, Fernando Hernández, Ricardo Parody, Juan Bargay, Joaquín Díaz-Mediavilla, José García-Laraña, Eduardo Rocha, Francisco Martínez, Conrado Campo, Carlos Solano, Jorge Sierra, Salut Brunet. Indicaciones del trasplante de precursores hematopoyéticos en Linfomas de Bajo Grado de malignidad. (Inluyendo el análisis del Registro del Grupo Cooperativo Español GEL/TAMO). En XXXVIII Reunión Nacional de la Asociación Española de Hematología-Hemoterapia. Málaga 1996.

J. García-Laraña, E. Conde, J. Sierra, JJ. Lahuerta, A. Domingo, J. García-Conde, D. Caballero, M. Gandarillas, R. Mataix, F. Martínez, J. Zuazu, D. Carrera, V. Rubio, J. Marín, E. Rocha, J. Díaz-Mediavilla, J. Maldonado, J. Besalduch, R. Arranz, MA. Sanz, F. Hernández, R. Parody, JM. Moraleda, JL. Bello, P. Vivancos, Grupo Cooperativo Español GEL/TAMO. Trasplante de células progenitoras hematopoyéticas en Linfomas de Células Grande. En XXXVIII Reunión Anual de la Asociación Española de Hematología y Hemoterapia. Málaga. Noviembre 1996.

MD. Caballero, E. Conde, M. Gandarillas, J. Lahuerta, R. Arranz, V. Rubio, J. Sierra, S. Brunet, R. Parody, J. García-Laraña, J. Marín, D. Carrera, C. Campos, J. Rifón, JM. Moraleda, J. Zuazu, J. Besalduch, F. Hernández, J. Díaz-Mediavilla, J. Maldonado, MA. Sanz, JL. Bello, J. García-Conde, F. Martínez, por el Grupo GEL/TAMO. Tratamiento de los Linfomas Refractarios. En XXXVIII Reunión Anual de la Asociación Española de Hematología y Hemoterapia. Málaga. Noviembre 1996.

A. Sureda, JF. Tomás, J. Sierra, D. Caballero, J. García-Conde, JJ. Lahuerta, J. García-Laraña, I. Jarque, J. Maldonado, E. Conde, A. López, R. Mataix, J. Besalduch, J. Rifón, A. León, D. Carrera, F. Hernández, J. Callís, J. Moraleda, E. Bengoechea, MN. Fernández, A. Torres, S. Brunet, JM. Fernández-Rañada, E. Montserrat, J. San Miguel, C. Solano, A. Domingo-Albós, por el GEL/TAMO. Trasplante Autólogo de precursores hematopoyéticos en la Enfermedad de Hodgkin. En XXXVIII Reunión Anual de la Asociación Española de Hematología y Hemoterapia. Málaga. Noviembre 1996.

E. Conde, (Por el Grupo Cooperativo Español GEL/TAMO). Trasplante Autólogo de células progenitoras hematopoyéticas en pacientes con linfomas no-hodgkin de bajo grado. En IV Seminario sobre trasplante con células de sangre periférica . Coordinadores: Dr. J. Odriozola y Dra. D. Caballero. Sangre 1996 (Supl. 1); 41: 59-63.

A. Sureda, D. Caballero, J. García-Laraña, Y. Jarque, A. Lopez, R. Mataix, J. Rifon, JF. Tomas, E. Conde, J. Callis, J. Morey, F. Hernández, A. León, MN. Fernández, JJ. Lahuerta, E. Carrera, J. Sierra, A. Domingo-Albos, (Por el Grupo Cooperativo GEL/TAMO). Trasplante Autólogo de precursores hematopoyéticos recogidos de sangre periférica en la enfermedad de Hodgkin. Experiencia española. En IV Seminario sobre trasplante con células de sangre periférica. Coordinadores: Dr. J. Odriozola y Dra. D. Caballero. Sangre 1996 (Supl. 1); 41: 57-58.

JJ. Lahuerta. C. Grande, R. Bornstein,l J. Bargay, J de la Serna, P. Galan, MC Cruz, JR. García, S. Larregla, R. Toscano, MA. Montalban, J. Besalduch, J. Montero, A. Gomez. Altas dosis de ciclofosfamida, BCNU y VP-16 (CBV), soportadas con un segundo trasplante autólogo de precursores hematopoyéticos en pacientes con mieloma múltiple quimiosensible a 200 mg/m²de melfalán. En IV Seminario sobre trasplante con células de sangre periférica. Coordinadores: Dr. J. Odriozola y Dra. D. Caballero. Sangre 1996 (Supl. 1); 41: 70-75.

J. Sierra, E. Conde, J. San Miguel, JJ. Lahuerta, J.Marín, V. Rubio, S. Brunet, E. Montserrat, J. Odriozola, A. Juliá, J. Bargay, E. Rocha, D. Carrera, JM. Fernández-Rodríguez, R. Mataix, A. Torres, J. Maldonado, J. García-Conde, J. Díaz Mediavilla, M. Gandarillas, JL. Bello, JM. Moraleda, P. Vivancos, F. Hernández, MA. Sanz, D.Rubio, L. Palomera, A. Iriondo. Factores predictivos de la recuperación hematológica tras autotrasplante de progenitores hematopoyéticos en LNH. Experiencia del Grupo Español GEL/TAMO. Sangre 1996 (Supl. 3); 41:89.

E. Conde, D. Caballero, A. Iriondo, C. Campo, J. García-Laraña, J.Besalduch, J.Maldonado, A. León, D. Carrera, J. Zuazu, J. García-Conde, F. Bosch, JL. Bello, L. Palomera, A. Zubizarreta por el Grupo GEL/TAMO. Megachop vs. Trasplante autólogo de células progenitores hematopoyéticas en pacientes con LNH de alto riesgo. Estudio prospectivo controlado. Sangre 1996 (Supl. 3); 41:90.

I. Gutierrez, E. Conde, M. Gandarillas, J. Baro, A. Iriondo, A. Zubizarreta. Creación de una base de datos para el registro de trasplantes de células progenitores hematopoyéticas en linfomas y su utilización por el grupo GelTamo. Centro de Cálculo y Servicio de Hematología-Hemoterapia del Hospital Univ. Marqués de Valdecilla. Universidad de Cantabria. Santander. Sangre 1996 (Supl. 3); 41:90.

V. Rubio, J. Marín, J. San Miguel, J. Sierra, C. Richard, S. Larregla, R. Arranz, R. Mataix, D. Carrera, J. Pérez Oteyza, R. Parody, A. López, A. Torres, J.García-Conde, M. Gandarillas, A. Sureda, J. Besalduch, B. Cuesta, M. Pérez Encinas, MC. Artacho, JM. Moraleda, J. Díaz Mediavilla, MA. Sanz, F. Hernández, P. Vivancos , D. Rubio, L. Palomera, E. Conde. Autotrasplante de progenitores hematopoyéticos en 37 linfomas de Burkitt. Experiencia del grupo cooperativo español GEL/TAMO. Sangre 1996 (Supl. 3); 41:104.

R. Arranz, J. Baro, E. Montserrat, D. Caballero, C. Grande, MJ. Vidal , A. León, A. Domingo, JM. FernándezRañada, J. López, J. Bueno, F. Martínez, J. Bargay, C. Rayón, V. Vicente, J. Rifón, C. Campos, R. Parody, MJ. Rabuñal, C. Solano , A. Villegas, J. Maldonado, G. Sanz, M. Gandarillas, F. Hernández, L. Palomera, D. Rubio, P. Vivancos, E. Conde. Autotrasplante de progenitores hematopoyéticos en 68 linfomas linfoblásticos. Experiencia del Grupo Español GEL/TAMO. Sangre 1996 (Supl. 3); 41:104.

1995

1994

A. Iriondo, J. García-Conde, A. Domingo (Por el Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea G EL/TAMO.) Bone Marrow Transplantation in Hodgkin's disease: When should it be considered?. Hematology Reviews 1994; 8:313-321.

E. Conde, J. Sierra, A. Iriondo, A. Domingo, J. García-Laraña, J. Marín, D. Caballero, F. Martínez, A. León, J. García-Conde, F. Hernández, D. Carrera, R. Mataix, J. Zuazu, B. Cuesta, J. Díaz Mediavilla, J. Lahuerta, C. Richard, J. Baro, E. Montserrat,. Prognostic factors in patients who received autologous bone marrow transplantation for non-hodgkin's lymphoma. Report of 104 patients from the Spanish Cooperative Group GEL/TAMO. Bone Marrow Transplant 1994; 14:279-286.

A. Domingo Albós, A. Sureda, A. Iriondo, JF. Tomás, A. León, R. Mataix, MA. Sanz, E. Bengoechea, D. Caballero, F. Hernández, J. García-Laraña, J. Sierra, A. torres, E. Rocha , C. Solano, J. Maldonado, J. Besalduch, S. Brunet, J. Rifón, JM. Fernández-Rañada, E. Conde, J. Odriozola, J. García-Conde. Grupo Español de Linfomas/Trasplante Autólogo de Médula osea GEL/TAMO. Quimio-radioterapia a altas dosis y trasplante autólogo de Médula Osea en la enfermedad de Hodgkin de mal pronóstico en primera remisión completa. Sangre 1994; 39:54.

A. Domingo Albós, A. Sureda, A. Iriondo, JF.Tomás, E. Bengoechea, D. Caballero, J. Zuazu, F. Hernández, J. García-Laraña, J. Sierra, A. Torres, E. Rocha, C. Solano, R. Mataix, J. Maldonado, A. León, J. Besalduch, S. Brunet, J. Rifón, MA. Sanz, JM. Fernández-Rañada, E. Conde, J. Odriozola, J. García-Conde. Grupo Español de Trasplante de Linfomas/Trasplante Autólogo de Médula Osea GEL/TAMO. Quimio-radioterapia a altas dosis seguido de trasplante autólogo de Médula Osea en la enfermedad de Hodgkin 2¦ o 3¦ remisión completa. Sangre 1994; 39:54.

J. Sierra, E. Conde (Por el Grupo GEL/TAMO). Megaterapia en los linfomas no-hodgkinianos: experiencia del grupo español GEL/TAMO. Bio-reguladores. Reviews on bio-regulators. Springer-Verlag Ibérica. 1994; 3:151-152.

1993

1992

1991

Artículos

Publicaciones internacionales

Sobre Geltamo

ÁREA PRIVADA

Actividades Científicas

SEDE VIRTUAL

Proyectos

REDCAP

Buscar